Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Irina P. Miller"'
Autor:
Roman Hovorka, M. Nazeem Nanjee, C. Justin Cooke, Irina P. Miller, Waldemar L. Olszewski, Norman E. Miller
Publikováno v:
Journal of Lipid Research, Vol 47, Iss 5, Pp 975-981 (2006)
Apolipoprotein kinetics are customarily determined by modeling time curves of specific radioactivity or isotopic enrichment in plasma after intravenous infusion of radiolabeled lipoproteins or stable isotope-enriched amino acids. However, this provid
Externí odkaz:
https://doaj.org/article/af7d4c4b91b747ab813fe39a20f8ca8f
Autor:
Mitsuaki Ishihara, Takeshi Kujiraoka, Tadao Iwasaki, Makoto Nagano, Mayumi Takano, Jun Ishii, Masahiro Tsuji, Hajime Ide, Irina P. Miller, Norman E. Miller, Hiroaki Hattori
Publikováno v:
Journal of Lipid Research, Vol 46, Iss 9, Pp 2015-2022 (2005)
Apolipoprotein A-V (apoA-V) is a recently discovered apolipoprotein that appears to have a role in plasma triglyceride (TG) transport. We have developed an ELISA for apoA-V using monoclonal antibodies that has a lower limit of detection of 0.3 ng/ml
Externí odkaz:
https://doaj.org/article/b3670d93d26e4f0a8937081586cf97a9
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Frontiers in Pharmacology
Frontiers in Pharmacology
Cholesterol esterification in high density lipoproteins (HDLs) by lecithin:cholesterol acyltransferase (LCAT) promotes unesterified cholesterol (UC) transfer from red cell membranes to plasma in vitro. However, it does not explain the transfer of UC
Autor:
Waldemar L. Olszewski, Roman Hovorka, C. Justin Cooke, M. Nazeem Nanjee, Irina P. Miller, Norman E. Miller
Publikováno v:
Journal of Lipid Research, Vol 47, Iss 5, Pp 975-981 (2006)
Apolipoprotein kinetics are customarily determined by modeling time curves of specific radioactivity or isotopic enrichment in plasma after intravenous infusion of radiolabeled lipoproteins or stable isotope-enriched amino acids. However, this provid
Autor:
Masahiro Tsuji, Taro Maruyama, Motoo Tsushima, Satoshi Saito, Mitsuaki Ishihara, Hiroaki Hattori, Yoshiyuki Sasaguri, Takahiro Ueno, Jun Ishii, Irina P. Miller, Tohru Egashira, Takayuki Fujioka, Yoshikazu Miwa, Tadao Iwasaki, Takeshi Kujiraoka, Norman E. Miller
Publikováno v:
Journal of Atherosclerosis and Thrombosis. 13:314-322
Apolipoprotein (apo) J, clusterin, is ubiquitously expressed in many tissues, and is a component of high-density lipoproteins (HDLs). There is experimental evidence that it may be anti-atherogenic through its effects on cholesterol transport, smooth
Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid
Autor:
Norman E. Miller, Hiroaki Hattori, Tomoichiro Oka, Takeshi Kujiraoka, Tadao Iwasaki, Waldemar L. Olszewski, Irina P. Miller, M. Nazeem Nanjee
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 304(3)
Although much is known about the remodeling of high density lipoproteins (HDLs) in blood, there is no information on that in interstitial fluid, where it might have a major impact on the transport of cholesterol from cells. We incubated plasma and af
Autor:
Norman E. Miller, Pauline Sutton, Irina P. Miller, Gunilla Olivecrona, Keith N. Frayn, Matthew Hazell, C. Charles Michel, M. Nazeem Nanjee, Waldemar L. Olszewski, Sandy M. Humphreys
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 301(4)
Peptides secreted by adipose tissue (adipokines) may enter blood via capillaries or lymph. The relative importance of these pathways for a given adipokine might influence its biological effects. Because this has not been studied in any species, we me
Autor:
Norman E. Miller, Takeshi Kujiraoka, Masahiro Tsuji, Tadao Iwasaki, Mayumi Takano, Mitsuaki Ishihara, Hiroaki Hattori, Makoto Nagano, Hajime Ide, Jun Ishii, Irina P. Miller
Publikováno v:
Journal of Lipid Research, Vol 46, Iss 9, Pp 2015-2022 (2005)
Apolipoprotein A-V (apoA-V) is a recently discovered apolipoprotein that appears to have a role in plasma triglyceride (TG) transport. We have developed an ELISA for apoA-V using monoclonal antibodies that has a lower limit of detection of 0.3 ng/ml